AI Startup kausable Raises €12M; Bruker Acquires Noscendo

In a significant development for the German AI sector, Heidelberg-based startup kausable has successfully closed a €12 million seed funding round. The investment was led by prominent venture capital firms, including UVC Partners and Entourage, with participation from High-Tech Gründerfonds (HTGF) and Mätch VC, alongside contributions from angel investors. This capital infusion is earmarked for expanding the company's nine-person team and further advancing its proprietary AI technology.

Kausable, founded in 2025 by Johannes Haux, Gregor Ramien, and Benjamin Herdeanu, is pioneering a novel approach to artificial intelligence. Their core innovation lies in developing "causal AI" capable of independent adaptation to new contexts with minimal data input, a significant departure from traditional machine learning models that often require extensive training datasets. This capability positions kausable to address complex challenges across various industries where data scarcity or rapid environmental changes are common.

The broader market for AI solutions continues its robust expansion, with global AI spending projected to reach hundreds of billions of dollars in the coming years. Startups like kausable, focusing on more efficient and adaptable AI, are well-placed to capture market share. Their technology could unlock new applications in fields ranging from predictive maintenance to personalized medicine, areas where real-time, context-aware decision-making is paramount.

In a separate transaction within the life sciences sector, Bruker Corporation has acquired the assets of the now-insolvent German MedTech firm Noscendo. Noscendo, established in 2018, specialized in software-driven solutions for pathogen identification and characterization. Despite attracting approximately €27 million in prior funding from investors such as Earlybird, Wieland Capital, Paua Ventures, HTGF, and Revent, the company faced insolvency proceedings in June 2026 following a failed funding round.

This acquisition by Bruker, a global leader in life science instrumentation and analytical solutions, highlights the ongoing consolidation within the health technology space. While Noscendo's journey ended in insolvency, its technological contributions in pathogen detection may find new life and application under Bruker's established market presence. The acquisition underscores the inherent risks and rewards in the MedTech startup ecosystem, where innovation can be highly valuable but market adoption and funding are critical determinants of success.

The German venture capital scene also saw notable activity with Lakestar announcing the closure of its $300 million DefenseTech and Dual-Use fund, signaling a strategic shift towards specialized investment areas. Concurrently, healthcare giant Fresenius launched its own venture arm, Fresenius Ventures, committing at least €200 million over five years to startups in MedTech, digital health, and nutrition. Additionally, the state of Baden-Württemberg introduced BW-Capital, a new investment company with an initial €50 million to support technology-focused companies, including those in DefenseTech, AI, and Life Sciences. These strategic moves by established players and regional initiatives underscore a dynamic investment environment focused on critical and emerging technologies.